Global Rheumatoid Arthritis (RA) Pipeline Market Research Report 2022: Comprehensive Insights About 120+ Companies and 120+ Pipeline Drugs -

·4 min read

DUBLIN, May 25, 2022--(BUSINESS WIRE)--The "Rheumatoid Arthritis - Pipeline Insight, 2022" clinical trials has been added to's offering.

This "Rheumatoid Arthritis- Pipeline Insight, 2022" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Rheumatoid Arthritis pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis.

Rheumatoid Arthritis Emerging Drugs Chapters

This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rheumatoid Arthritis Emerging Drugs

Ozoralizumab: Taisho Pharmaceutical

Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNF? NANOBODY VHHs and one anti-serum albumin NANOBODY VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNF and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx. In March 2021, Taisho announced that it submitted an application for approval to manufacture and market the anti-TNF NANOBODY therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).

ABX 464 : Abivax

ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA, called miR-124, with potent anti-inflammatory properties. ABX464 showed a very favorable tolerability profile with mainly mild to moderate and transient side effects.


Ianalumab is an anti-B-cell activating factor (BAFF) receptor antibody which is administered subcutaneously. The drug is being investigated in Phase 2 stage of development for the treatment of Rheumatoid Arthritis.


BAY 1830839 is a novel small molecule inhibitor of IRAK4 identified by a medicinal chemistry optimization program. Key features of the compound are high potency (IC50 of 3 nM) in a biochemical assay, excellent kinase selectivity and a good overall PK profile making the compound a valuable tool for in vivo studies. The drug is being investigated in Phase 1 stage of development for the treatment of Rheumatoid Arthritis.

Rheumatoid Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Rheumatoid Arthritis

There are approx. 120+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. phase III include, Taisho Pharmaceutical

Rheumatoid Arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis drugs.

Key Questions Answered

  • How many companies are developing Rheumatoid Arthritis drugs?

  • How many Rheumatoid Arthritis drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Rheumatoid Arthritis and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Abivax

  • Kymera Therapeutics

  • Akari Therapeutics

  • Sierra Oncology

  • Neutrolis Therapeutics

  • Centivax

  • Taisho

  • Hope Biosciences

  • UCB

  • Galmed Pharmaceuticals

  • Celon Pharma

  • Jiangsu Hengrui Medicine Co.

  • Cyxone

  • Oryn Therapeutics

Key Products

  • ABX464

  • KT 474

  • Nomacopan

  • Momelotinib

  • NTR 441

  • Anti-CXCR5 antibody

  • Ozoralizumab

  • HB adMSCs

  • Amilo-5MER

  • CPL-409116

  • SHR 0302

For more information about this clinical trials report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting